TD Asset Management Inc Buys 98,201 Shares of Avantor, Inc. (NYSE:AVTR)

TD Asset Management Inc increased its stake in shares of Avantor, Inc. (NYSE:AVTR) by 3.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,240,593 shares of the company’s stock after purchasing an additional 98,201 shares during the quarter. TD Asset Management Inc’s holdings in Avantor were worth $68,701,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of AVTR. Norges Bank bought a new stake in Avantor in the fourth quarter worth about $156,455,000. CCLA Investment Management lifted its stake in shares of Avantor by 147,220.3% during the 1st quarter. CCLA Investment Management now owns 4,720,144 shares of the company’s stock worth $120,828,000 after acquiring an additional 4,716,940 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Avantor during the 4th quarter valued at $93,433,000. Avidity Partners Management LP bought a new position in Avantor in the 4th quarter valued at $48,442,000. Finally, Magnetar Financial LLC purchased a new stake in Avantor in the first quarter worth $35,154,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on AVTR shares. Barclays boosted their target price on shares of Avantor from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Evercore ISI lowered their price objective on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Stifel Nicolaus raised their target price on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. TD Cowen boosted their price target on Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, July 29th. Finally, Wells Fargo & Company initiated coverage on Avantor in a research report on Tuesday, August 27th. They set an “overweight” rating and a $30.00 price target on the stock. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Avantor has a consensus rating of “Moderate Buy” and an average price target of $27.40.

Insider Transactions at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.50% of the company’s stock.

Avantor Stock Performance

AVTR stock opened at $25.55 on Friday. Avantor, Inc. has a one year low of $16.63 and a one year high of $28.00. The firm has a market cap of $17.35 billion, a price-to-earnings ratio of 65.50, a PEG ratio of 2.64 and a beta of 1.32. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. The firm has a 50-day simple moving average of $23.86 and a two-hundred day simple moving average of $24.20.

Avantor (NYSE:AVTR) last posted its earnings results on Friday, July 26th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. Avantor had a net margin of 5.28% and a return on equity of 12.40%. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.70 billion. On average, equities analysts forecast that Avantor, Inc. will post 1.01 EPS for the current fiscal year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.